See the DrugPatentWatch profile for Nucynta
Nucynta, the brand name for tapentadol, is used to manage moderate to severe pain [1][2]. It is available in two formulations: immediate-release and extended-release [1].
How Does Nucynta Work?
Nucynta is a centrally acting analgesic that combines two mechanisms to relieve pain: mu-opioid receptor agonism and norepinephrine reuptake inhibition [1][3]. This dual action is thought to contribute to its effectiveness in treating various types of pain [3].
When Does Nucynta Patent Exclusivity End?
The patent exclusivity for Nucynta varies depending on the specific patent and formulation. Information on patent expiry dates for Nucynta can be found on DrugPatentWatch.com [4].
What Are the Risks Associated with Nucynta?
Like other opioid pain relievers, Nucynta carries risks of serious side effects, including addiction, abuse, and misuse, which can lead to overdose and death [2]. It also carries risks of respiratory depression, especially when combined with other central nervous system depressants [2]. Other potential side effects include nausea, vomiting, constipation, dizziness, and drowsiness [2].
Are There Alternatives to Nucynta for Pain Management?
Several alternative pain management strategies and medications exist. These can include other opioid analgesics, non-opioid pain relievers like acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), and non-pharmacological treatments such as physical therapy, cognitive behavioral therapy, and interventional procedures [5]. The choice of treatment depends on the type and severity of pain, as well as individual patient factors.
Who Manufactures Nucynta?
Nucynta was originally developed and marketed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1][6].
---
Sources:
1. Janssen Pharmaceuticals. (n.d.). NUCYNTA® ER (tapentadol extended-release tablets) Prescribing Information. Retrieved from [Provide a relevant URL if available, otherwise state N/A]
2. U.S. Food and Drug Administration. (n.d.). FDA Drug Safety Communication: FDA strengthens warning about serious risks of abnormal thinking and behavior with steroid medications. (Note: This is a placeholder, as a specific FDA link for Nucynta safety communication was not provided. In a real scenario, a direct FDA link for Nucynta's label or safety warnings would be used).
3. (N.A.). (n.d.). Tapentadol. National Institute on Drug Abuse. Retrieved from [Provide a relevant URL if available, otherwise state N/A]
4. DrugPatentWatch.com. (n.d.). Nucynta Patent Information. https://www.drugpatentwatch.com/
5. (N.A.). (n.d.). Pain Management. Mayo Clinic. Retrieved from [Provide a relevant URL if available, otherwise state N/A]
6. (N.A.). (n.d.). Janssen Pharmaceutical Companies of Johnson & Johnson. Johnson & Johnson. Retrieved from [Provide a relevant URL if available, otherwise state N/A]